

Patient ID SA00143835	Patient Name SAMPLEREPORT, TESTINGPATIENT	Birth Date 1987-12-28	Gender F	Age 33
Order Number SA00143835	Client Order Number SA00143835	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 05 Apr 2021 00:00		

Apixaban, Anti-Xa, P

Result Name	Value	Unit	Reference Value	Performing Site
  Apixaban, Anti-Xa, P	12	ng/mL	<10	1 MCR

Interpretation

Therapeutic reference ranges have not been established. Median (5th-95th percentile) peak and trough levels observed in clinical trials are shown.

Non-valvular atrial fibrillation:

Peak levels (2–4 hrs post dose):

2.5 mg (twice daily): 123 (69–221) ng/mL
5 mg (twice daily): 171 (91–321) ng/mL

Trough levels (10–12 hrs post dose):

2.5 mg (twice daily): 79 (34–162) ng/mL
5 mg (twice daily): 103 (41–230) ng/mL

Prevention and treatment of venous thromboembolism:

MCR

Peak levels (2–4 hrs post dose):

2.5 mg (twice daily): 67 (30–153) ng/mL
5 mg (twice daily): 132 (59–302) ng/mL
10 mg (twice daily): 251 (111–572) ng/mL

Trough levels (10–12 hrs post dose):

2.5 mg (twice daily): 32 (11–90) ng/mL
5 mg (twice daily): 63 (22–177) ng/mL
10 mg (twice daily): 120 (41–335) ng/mL

Cautions

This assay is not indicated for monitoring low molecular weight heparin (LMWH) or unfractionated heparin (UFH). Presence of UFH and LMWH will falsely elevate apixaban anti-Xa levels.

MCR

Received: 05 Apr 2021 11:44

Reported: 05 Apr 2021 11:45

Laboratory Notes

- 1 This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292